

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort NeuroTech Limited

微創腦科學有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2172)

POSITIVE PROFIT ALERT

This announcement is made by MicroPort NeuroTech Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2022 (the “**FY 2022**”) and other currently available information, the Group expects to record for FY 2022:

- (i) Revenue ranging from approximately RMB520 million to RMB540 million, representing an increase of approximately 36% to 41% as compared to that of the year ended 31 December 2021 (the “**FY 2021**”), among which, the revenue generated from the Group’s overseas operation exceeded RMB20 million for the first time, representing an increase of exceeded 3,200% as compared to that of FY 2021; and
- (ii) Adjusted net profit* ranging from approximately RMB100 million to RMB120 million, representing an increase of approximately 15% to 38% as compared to that of FY 2021.

* The Company used adjusted net profit as non-HKFRS measures, eliminating potential impacts of profit/loss of associates and certain non-cyclical or one-time expense items (including accrued interest expenses on preferred shares, listing expenses, share-based payment expenses, etc.).

Based on currently available information, the Board considers that the aforementioned expected increase in the revenue and profitability of the Group is principally attributable to the following reasons:

- (i) Tendering and admission of major new products launched by the Group in recent years (including NUMEN[®] Coil Embolization System, Bridge[®] Rapamycin Target Eluting Vertebral Artery Stent System and U-track[®] Intracranial Support Catheter System) into hospitals has been accelerated, which led to fast realization of revenue;
- (ii) Through integration of channels and resources and continuous development of lower-tier markets, the market share leading products of the Group (including Tubridge[®] Flow-diverting Stent and Asahi[®] Neurovascular Guidewires) have constantly consolidated competitive advantages and maintained positive growth trends;
- (iii) Revenue generated from Group's overseas operation achieved breakthrough growth in FY 2022 exceeding RMB20 million. During FY 2022, the Group's products were newly commercialized in six overseas countries and regions, including the United States of America, Korea, Brazil and Europe; and
- (iv) The Group's newly approved products in FY 2022 (including Neurohawk[®] Stent Thrombectomy Device and Diveer[™] Intracranial Balloon Dilatation Catheter) have commenced commercialization and contributed to the growth of the Group's revenue.

The Company is in the process of finalizing the consolidated annual results for FY 2022. The information set out in this announcement is only a preliminary assessment made by the Board based on the unaudited consolidated management accounts of the Group and other currently available information of the Company. Such information have not been audited or reviewed by the independent auditors or audit committee of the Company. The Group expects to record net loss for FY 2022 in accordance with HKFRS without eliminating potential impacts of profit/loss of associates and certain non-cyclical or one-time expense items as disclosed above. Shareholders and potential investors of the Company are advised to read the Company's annual results announcement for FY 2022 carefully, which is expected to be published by the end of March 2023.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
MicroPort NeuroTech Limited
Mr. Peng Bo
Chairman

Hong Kong, 13 January 2023

As at the date of this announcement, the Board comprises Mr. Xie Zhiyong and Mr. Wang Yiqun Bruce as the executive directors; Mr. Peng Bo, Mr. Wang Lin and Ms. Wu Xia as the non-executive directors; and Dr. Xu Yi, Dr. Zhang Haixiao and Mr. Siu Chi Hung as the independent non-executive directors.